Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852)
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
🩺 Plain-English Summary (8th-Grade Level)
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- University of California, San Francisco — San Francisco, California
- University of Miami Sylvester Cancer Center — Miami, Florida
- University of Chicago Medical Center — Chicago, Illinois
- National Cancer Institute — Bethesda, Maryland
- Columbia University Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke University — Durham, North Carolina
- University of Pennsylvania — Philadelphia, Pennsylvania
- SCRI Oncology Partners — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Princess Margaret Cancer Centre — Toronto, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mesothelioma
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma — Baltimore, Maryland
- A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors — Los Angeles, California
- Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma — Tampa, Florida
- Olaparib in Patients With HRD Malignant Mesothelioma — Chicago, Illinois
- A Study of Sacituzumab Govitecan in People With Mesothelioma — Basking Ridge, New Jersey
Explore by condition: All Mesothelioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.